Meghan Fitzgerald

Meghan M.
Fitzgerald is the founder of K2 HealthVentures Group LLC, founded in 2018.
Dr. Fitzgerald is also the founder of K2 HealthVentures LLC..
Current jobs include Independent Director at Tenet Healthcare Corp.
since 2018, Independent Director at Roivant Sciences Ltd. since 2023, Director at Seniorlink, Inc., Director at Quanta Dialysis Technologies Ltd. since 2022, Senior Advisor at Wellspring Capital Management Group LLC, Assistant Professor-Health Policy at The Trustees of Columbia University in The City of New York since 2014, Member at Harvard Kennedy School of Government, and Advisor at Thimble Point Acquisition Corp.
II.
Former jobs include Chief Executive Officer & Managing Partner at LetterOne Holdings SA, Senior Director-Strategic Planning-Human Health at Pfizer Inc. from 2001 to 2006, Independent Director at Concert Pharmaceuticals, Inc. from 2016 to 2018, Director at Gelesis, Inc., Director at Follica, Inc., Independent Non-Executive Director at Arix Bioscience Plc from 2017 to 2019, Director at Destination Pet LLC, Independent Director at Thimble Point Acquisition Corp.
in 2021, President-Specialty Solutions at Cardinal Health, Inc. from 2015 to 2016, Principal at Merck & Co., Inc., Chief Business Officer & Vice President at Vion Pharmaceuticals, Inc., Senior VP-New Markets International Division at Medco Health Solutions, Inc. from 2008 to 2010, Principal at Pfizer Global Pharmaceuticals, Inc., Principal at Sanofi-Synthelabo, Inc., President at Cardinal Health 122 LLC, and Managing Partner at Letterone Investment Holdings SARL from 2016 to 2019.
Education includes graduate degree from The Trustees of Columbia University in The City of New York, undergraduate degree from Fairfield University, and doctorate from New York Medical College.